6533b7dafe1ef96bd126e1e8
RESEARCH PRODUCT
Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index
Marcus Schmidtsubject
0301 basic medicineOncologyChemotherapymedicine.medical_specialtyCyclophosphamideDose-dense chemotherapybusiness.industrymedicine.medical_treatmentReview Articlemedicine.diseaseVinorelbineMetronomic ChemotherapyMetastatic breast cancerCapecitabine03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicinemedicineSurgerybusinessmedicine.drugdescription
Despite the advancement of targeted therapies in metastatic breast cancer, chemotherapy is still of pivotal importance. The concept of dose density is known to increase the efficacy of chemotherapy. In metastatic disease, preservation of the quality of life is equally important. Because of this, weekly regimens are a cornerstone in metastatic disease. Taxanes like paclitaxel or nab-paclitaxel as well as antracyclines are often used in palliative treatment. Further advances to increase dose density have led to the concept of daily metronomic schedules with oral chemotherapeutic drugs like cyclophosphamide, capecitabine, or vinorelbine. Metronomic chemotherapy affects tumor angiogenesis and also weakens immunosuppressive regulatory T cells, promoting better control of tumor progression. Weekly or daily dose-dense regimens are a reasonable compromise between efficacy and toxicity to improve the therapeutic index. This is most important for the treatment of chronic disease where palliation and preservation of quality of life are vital.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-12-22 |